Meta Information

ID:dasatinib-quercetin

Name:Dasatinib and Quercetin

Schema Version:1.5

Title

Dasatinib + Quercetin

Alternate Names

• D+Q
• Senolytics

Intervention Type

synergistic_therapy

Expected Cost Mean

Low Cost:

500

High Cost:

2500

Cost Type:

one time

Description:

Cost per intermittent dosing cycle, dominated by prescription Dasatinib.

Summary

Dasatinib + Quercetin is a senolytic combination therapy designed to selectively induce apoptosis (programmed cell death) in senescent cells. These 'zombie' cells accumulate with age, secreting a cocktail of inflammatory proteins (the SASP) that damage surrounding tissues and contribute to numerous age-related diseases. By clearing these cells, D+Q aims to reduce systemic inflammation, improve tissue function, and potentially delay, prevent, or alleviate age-related conditions.

Purpose

A senolytic therapy that clears aged 'zombie' cells.

Card Summary

A senolytic therapy that selectively eliminates senescent 'zombie' cells, which accumulate with age and drive inflammation and tissue dysfunction.

Drug Class

Drugs In Class

Empty Array

Impact

Score:

7.5

Justification:

Potentially rejuvenates tissues by targeting a key driver of aging—senescent cells.

Evidence

Grade:

B

Score:

6.5

Justification:

Positive results in animal models and small human trials for specific conditions.

Safety

Score:

7.8

Justification:

Involves a potent prescription chemotherapy drug with a significant side effect profile.

Flags

• Requires a prescription and close medical supervision.
• Dasatinib is a chemotherapy drug with numerous potential side effects, including fatigue, fluid retention, and myelosuppression.
• Potential for drug interactions, especially with CYP3A4 inhibitors/inducers (e.g., grapefruit juice).
• Long-term safety of intermittent use for healthspan is not yet established.

Verdict

A potent but high-risk senolytic requiring strict medical guidance.

Created

2026-04-23T23:24:55.391131Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

oral

Scope:

• systemic

Indication

Focus:

healthspan

Description:

Dasatinib + Quercetin is a senolytic combination therapy designed to selectively induce apoptosis (programmed cell death) in senescent cells. These 'zombie' cells accumulate with age, secreting a cock...

Typical Protocol

• Intermittent dosing, such as Dasatinib 100mg and Quercetin 1000-1250mg daily for 2-3 consecutive days, repeated monthly or quarterly.